ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves First Drug to Treat Rare Metabolic Disorder
December 11, 2020The U.S. Food and Drug Administration (FDA) approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. -
Alnylam's RNAi therapeutic Oxlumo gets EU green light
November 23, 2020Alnylam Pharmaceuticals has scored an approval from the European Commission for its RNAi therapeutic Oxlumo, for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
Pharma Sources Insight January 2025
